Budesonide is recommended as one of the first-line drugs for treatment of eosinophilic esophagitis (EoE), a chronic immune-mediated inflammatory disease, and in a recent study researchers updated a ...

A recent study found that budesonide-based triple therapy was just as effective as fluticasone-based triple therapy, with less incidence of death and severe pneumonia. A study published in Journal of ...

As asthma symptoms worsen, patients typically rely on short-acting β 2-agonist (SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves patients at risk for severe asthma ...

Credit: AstraZeneca. Airsupra combines albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. Airsupra ® (albuterol/budesonide) is now available for the as-needed ...

Young woman using asthma inhaler at home. The NDA submission is supported by data from the phase 3 MANDALA trial, which included 3132 patients with moderate to severe asthma. The Food and Drug ...

Patients with eosinophilic oesophagitis (EoE) unresponsive to off-label swallowed topical corticosteroids (STCs) demonstrated a positive response to an oesophageal-targeted budesonide formulation.

Please provide your email address to receive an email when new articles are posted on . The study treatment, PT027, is a potential first-in class inhaled, fixed-dose combination rescue medication ...

Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.

As-needed use of albuterol–budesonide has been shown to result in a significantly lower risk of severe asthma exacerbation than as-needed use of albuterol alone among patients with moderate-to-severe ...

Among 1,059 infants, survival without BPD occurred in 25.6% of infants who received budesonide and surfactant and 22.6% of infants who received only surfactant (adjusted risk difference 2.7%, 95% CI ...